PITPNA

Summary

PITPNA (phosphatidylinositol transfer protein alpha, HGNC:9001) is a protein-coding gene on chromosome 17p13.3, encoding Phosphatidylinositol transfer protein alpha isoform (Q00169). Catalyzes the transfer of phosphatidylinositol (PI) and phosphatidylcholine (PC) between membranes.

This gene encodes a member of a family of lipid-binding proteins that transfer molecules of phosphatidylinositol or phosphatidylcholine between membrane surfaces. The protein is implicated in phospholipase C signaling and in the production of phosphatidylinositol 3,4,5-trisphosphate (PIP3) by phosphoinositide-3-kinase.

Source: NCBI Gene 5306 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 38 total
• Dosage sensitivity (ClinGen): haploinsufficiency no evidence, triplosensitivity no evidence
• MANE Select transcript: NM_006224

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9001
Approved symbol	PITPNA
Name	phosphatidylinositol transfer protein alpha
Location	17p13.3
Locus type	gene with protein product
Status	Approved
Aliases	VIB1A
Ensembl gene	ENSG00000174238
Ensembl biotype	protein_coding
OMIM	600174
Entrez	5306

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 8 protein_coding, 1 retained_intron, 1 nonsense_mediated_decay

ENST00000313486, ENST00000572004, ENST00000573056, ENST00000573231, ENST00000574991, ENST00000575288, ENST00000575895, ENST00000576010, ENST00000576722, ENST00000576761

RefSeq mRNA: 1 — MANE Select: NM_006224 NM_006224

CCDS: CCDS45563

Canonical transcript exons

ENST00000313486 — 12 exons

Exon	Start	End
ENSE00001198868	1562541	1562792
ENSE00002671330	1517718	1520538
ENSE00003480208	1548296	1548387
ENSE00003494939	1558529	1558559
ENSE00003516836	1535441	1535518
ENSE00003551483	1538869	1538952
ENSE00003575272	1521579	1521645
ENSE00003640531	1534099	1534221
ENSE00003652921	1541566	1541640
ENSE00003669391	1553004	1553149
ENSE00003787279	1535182	1535292
ENSE00003789372	1543020	1543027

Expression profiles

Bgee: expression breadth ubiquitous, 299 present calls, max score 99.69.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 50.3918 / max 431.3695, expressed in 1821 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
163735	50.3519	1821
163733	0.0161	3
163734	0.0122	3
163731	0.0074	2
163732	0.0041	1

Top tissues by expression

302 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pigmented layer of retina	UBERON:0001782	99.69	gold quality
retina	UBERON:0000966	99.66	gold quality
parotid gland	UBERON:0001831	97.55	gold quality
pons	UBERON:0000988	97.28	gold quality
skin of leg	UBERON:0001511	96.51	gold quality
lateral nuclear group of thalamus	UBERON:0002736	96.51	gold quality
skin of abdomen	UBERON:0001416	96.26	gold quality
monocyte	CL:0000576	96.21	gold quality
saliva-secreting gland	UBERON:0001044	96.19	gold quality
minor salivary gland	UBERON:0001830	95.98	gold quality
prefrontal cortex	UBERON:0000451	95.91	gold quality
esophagus mucosa	UBERON:0002469	95.90	gold quality
mononuclear cell	CL:0000842	95.89	gold quality
mouth mucosa	UBERON:0003729	95.88	gold quality
right frontal lobe	UBERON:0002810	95.84	gold quality
leukocyte	CL:0000738	95.78	gold quality
zone of skin	UBERON:0000014	95.75	gold quality
stromal cell of endometrium	CL:0002255	95.69	gold quality
gingiva	UBERON:0001828	95.66	gold quality
islet of Langerhans	UBERON:0000006	95.39	gold quality
rectum	UBERON:0001052	95.34	gold quality
gingival epithelium	UBERON:0001949	95.34	gold quality
small intestine Peyer’s patch	UBERON:0003454	95.25	gold quality
smooth muscle tissue	UBERON:0001135	95.19	gold quality
endothelial cell	CL:0000115	95.10	gold quality
frontal cortex	UBERON:0001870	95.10	gold quality
frontal lobe	UBERON:0016525	95.10	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	95.09	gold quality
gall bladder	UBERON:0002110	95.06	gold quality
upper arm skin	UBERON:0004263	94.95	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-GEOD-135922	yes	15.40
E-CURD-112	yes	3.83
E-MTAB-8060	no	138.63
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): TCF3

miRNA regulators (miRDB)

164 targeting PITPNA, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-9718	99.94	68.91	918
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-498-3P	99.91	71.27	1114
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780

Functional genomics

ClinGen dosage: haploinsufficiency 0 (no evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 6)

• the PITPalpha structure has to relax to allow access to the Ser166 site, and this may occur at the membrane surface where PI delivery is required for receptor-mediated PLC signaling (PMID:15322105)
• the apparent occurrence of an unusual TG 3’ splice site in intron 4 is discussed (PMID:17672918)
• This protein has been found differentially expressed in thalami from patients with schizophrenia. (PMID:20471030)
• Data show that phosphatidylinositol transfer protein alpha (PITPalpha) is involved in the function of mixed lineage kinase domain-like protein (MLKL) in necroptosis. (PMID:29104146)
• PDE10A Inhibition Reduces the Manifestation of Pathology in DMD Zebrafish and Represses the Genetic Modifier PITPNA. (PMID:33221436)
• Restoration of PITPNA in Type 2 diabetic human islets reverses pancreatic beta-cell dysfunction. (PMID:37460527)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	pitpnaa	ENSDARG00000039490
danio_rerio	pitpnab	ENSDARG00000044091
mus_musculus	Pitpna	ENSMUSG00000017781
rattus_norvegicus	Pitpna	ENSRNOG00000003846
caenorhabditis_elegans		WBGENE00021854

Paralogs (5): PITPNM2 (ENSG00000090975), PITPNM3 (ENSG00000091622), PITPNM1 (ENSG00000110697), PITPNC1 (ENSG00000154217), PITPNB (ENSG00000180957)

Protein

Protein identifiers

Phosphatidylinositol transfer protein alpha isoform — Q00169 (reviewed: Q00169)

All UniProt accessions (10): Q00169, I3L2X8, I3L3W1, I3L459, I3L471, I3L4C0, I3L4H1, I3L4U7, I3NI10, V9HWC5

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the transfer of phosphatidylinositol (PI) and phosphatidylcholine (PC) between membranes. Shows a preference for PI and PC containing shorter saturated or monosaturated acyl chains at the sn-1 and sn-2 positions. Preference order for PC is C16:1 > C16:0 > C18:1 > C18:0 > C20:4 and for PI is C16:1 > C16:0 > C18:1 > C18:0 > C20:4 > C20:3.

Subcellular location. Cytoplasm. Nucleus.

Activity regulation. Phosphatidylinositol transfer activity is inhibited by N-ethylmaleimide.

Similarity. Belongs to the PtdIns transfer protein family. PI transfer class I subfamily.

RefSeq proteins (1): NP_006215* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001666	PI_transfer	Family
IPR023393	START-like_dom_sf	Homologous_superfamily
IPR055261	PI_transfer_N	Domain

Pfam: PF02121

Catalyzed reactions (Rhea), 2 shown:

• a 1,2-diacyl-sn-glycero-3-phosphocholine(in) = a 1,2-diacyl-sn-glycero-3-phosphocholine(out) (RHEA:38571)
• a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol)(in) = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol)(out) (RHEA:38691)

UniProt features (46 total): helix 12, mutagenesis site 11, strand 8, binding site 6, turn 3, initiator methionine 1, chain 1, modified residue 1, region of interest 1, sequence conflict 1, compositionally biased region 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
9TA5	X-RAY DIFFRACTION	2.1
8PQO	X-RAY DIFFRACTION	2.3
1UW5	X-RAY DIFFRACTION	2.9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q00169-F1	95.51	0.91

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (6): 58; 60; 85; 89; 96; 194

Post-translational modifications (1): 215

Mutagenesis-validated functional residues (11):

Position	Phenotype
58	reduced phosphatidylinositol and phosphatidylcholine transfer activity.
58	complete loss of phosphatidylinositol transfer activity but no effect on phosphatidylcholine transfer activity.
58	reduced phosphatidylinositol transfer activity but no effect on phosphatidylcholine transfer activity.
60	complete loss of phosphatidylinositol transfer activity but no effect on phosphatidylcholine transfer activity.
85	reduced phosphatidylinositol transfer activity but no effect on phosphatidylcholine transfer activity.
85	reduced phosphatidylinositol and phosphatidylcholine transfer activity.
89	significant loss of phosphatidylinositol transfer activity but no effect on phosphatidylcholine transfer activity.
94	no effect on phosphatidylinositol transfer activity. resistant to inhibition by n-ethylmaleimide.
102	reduced phosphatidylinositol and phosphatidylcholine transfer activity.
187	no effect on phosphatidylinositol transfer activity.
202–203	significant loss of phosphatidylinositol and phosphatidylcholine transfer activity.

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-418890	Role of second messengers in netrin-1 signaling
R-HSA-8950505	Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation

MSigDB gene sets: 224 (showing top): TGGTGCT_MIR29A_MIR29B_MIR29C, MORF_MSH3, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, LFA1_Q6, PID_NETRIN_PATHWAY, GOBP_NEUROGENESIS, SP1_Q2_01, GOBP_ORGANOPHOSPHATE_ESTER_TRANSPORT, GTGCCTT_MIR506, WANG_ESOPHAGUS_CANCER_VS_NORMAL_DN, FONTAINE_PAPILLARY_THYROID_CARCINOMA_UP, GOBP_SENSORY_PERCEPTION_OF_LIGHT_STIMULUS, ATF3_Q6, GOBP_LIPID_METABOLIC_PROCESS

GO Biological Process (6): lipid metabolic process (GO:0006629), axonogenesis (GO:0007409), visual perception (GO:0007601), phospholipid transport (GO:0015914), lipid transport (GO:0006869), intermembrane lipid transfer (GO:0120009)

GO Molecular Function (10): lipid binding (GO:0008289), phosphatidylcholine intramembrane carrier activity (GO:0008525), phosphatidylinositol transfer activity (GO:0008526), phosphatidylcholine binding (GO:0031210), phosphatidylinositol binding (GO:0035091), phosphatidylcholine transfer activity (GO:0120019), phosphatidylglycerol binding (GO:1901611), protein binding (GO:0005515), obsolete phospholipid transporter activity (GO:0005548), quaternary ammonium group binding (GO:0050997)

GO Cellular Component (4): nucleus (GO:0005634), cytoplasm (GO:0005737), cytosol (GO:0005829), extracellular exosome (GO:0070062)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Netrin-1 signaling	1
Interleukin-12 signaling	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
lipid transport	2
binding	2
phospholipid binding	2
anion binding	2
cellular anatomical structure	2
primary metabolic process	1
cell morphogenesis involved in neuron differentiation	1
neuron projection morphogenesis	1
axon development	1
sensory perception of light stimulus	1
organophosphate ester transport	1
transport	1
lipid localization	1
membrane organization	1
intramembrane lipid carrier activity	1
phosphatidylinositol binding	1
lipid transfer activity	1
cation binding	1
quaternary ammonium group binding	1
phosphatidylcholine binding	1
phospholipid transfer activity	1
small molecule binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cytoplasm	1
extracellular vesicle	1

Protein interactions and networks

STRING

1060 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PITPNA	YWHAE	P29360	893
PITPNA	SCARF1	Q14162	857
PITPNA	BHLHA9	Q7RTU4	834
PITPNA	TRARG1	Q8IXB3	811
PITPNA	PAFAH1B1	P43034	804
PITPNA	CRK	P46108	764
PITPNA	TIMM22	Q9Y584	751
PITPNA	HIC1	Q14526	662
PITPNA	NXF1	Q9UBU9	591
PITPNA	SERPINF1	P36955	560
PITPNA	MNT	Q99583	494
PITPNA	CDIPT	O14735	428
PITPNA	MYO18A	Q92614	427
PITPNA	OSBP	P22059	426
PITPNA	NTN1	O95631	423
PITPNA	PRPH2	P23942	423

IntAct

40 interactions, top by confidence:

A	B	Type	Score
PLK1	EVI5	psi-mi:“MI:0914”(association)	0.660
CASP6	PITPNA	psi-mi:“MI:0915”(physical association)	0.560
LAMP2	PITPNA	psi-mi:“MI:0915”(physical association)	0.560
PITPNA	UQCRC1	psi-mi:“MI:0915”(physical association)	0.560
SH3GLB1	PITPNA	psi-mi:“MI:0915”(physical association)	0.560
SIRT3		psi-mi:“MI:0915”(physical association)	0.400
	TK2	psi-mi:“MI:0915”(physical association)	0.400
CSNK2B	PITPNA	psi-mi:“MI:0915”(physical association)	0.370
Dync1li1	SSR3	psi-mi:“MI:0914”(association)	0.350
Cdc26		psi-mi:“MI:0914”(association)	0.350
S1PR4	PITPNA	psi-mi:“MI:0914”(association)	0.350
	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
	HLA-C	psi-mi:“MI:0914”(association)	0.350
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350
LHCGR	FURIN	psi-mi:“MI:0914”(association)	0.350
PITPNB	PITPNA	psi-mi:“MI:0914”(association)	0.350
SSUH2	IGLC7	psi-mi:“MI:0914”(association)	0.350
PITPNB	PRKCA	psi-mi:“MI:0914”(association)	0.350
HSDL1	HBB	psi-mi:“MI:0914”(association)	0.350
DND1	UBA6	psi-mi:“MI:0914”(association)	0.350

BioGRID (37): PITPNA (Co-fractionation), PITPNA (Co-fractionation), PITPNA (Co-fractionation), PITPNA (Co-fractionation), PITPNA (Co-fractionation), PITPNA (Co-fractionation), PITPNA (Co-fractionation), UBE2L3 (Co-fractionation), PITPNA (Affinity Capture-MS), PITPNA (Affinity Capture-MS), PITPNA (Affinity Capture-MS), PITPNA (Affinity Capture-MS), PMVK (Affinity Capture-MS), MORF4L2 (Affinity Capture-MS), MLKL (Affinity Capture-MS)

ESM2 similar proteins: A8K855, O95299, P0CB89, P0CB90, P11881, P16446, P19824, P29994, P29995, P34942, P48603, P48738, P48739, P53810, P53811, P53812, P60670, P70227, Q00169, Q0E908, Q0MQB6, Q0MQB7, Q14571, Q14573, Q14643, Q14849, Q2HJ54, Q4G005, Q54VC7, Q5BJI9, Q5M7Y0, Q5R6F0, Q63269, Q6IQC7, Q6NRZ4, Q6P3Q6, Q7K556, Q8H1S0, Q8TAT6, Q8WN95

Diamond homologs: G5EEM9, O00562, O35954, O46606, P16446, P43125, P48738, P48739, P53810, P53811, P53812, Q00169, Q28CA0, Q2HJ54, Q3UHE1, Q54D93, Q54VC7, Q5R6F0, Q5U2N3, Q6NZC7, Q6ZPQ6, Q80YA3, Q8K4R4, Q8NEL9, Q8W5R2, Q9BZ71, Q9BZ72, Q9NCL7, Q9NCL8, Q9TR36, Q9U9P7, Q9UKF7, Q12204

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

38 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	18
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1977 predictions. Top by Δscore:

Variant	Effect	Δscore
17:1534093:ACTT:A	donor_loss	1.0000
17:1534095:TTA:T	donor_loss	1.0000
17:1534096:TACTT:T	donor_loss	1.0000
17:1534097:A:AC	donor_gain	1.0000
17:1534097:A:T	donor_loss	1.0000
17:1534097:ACTT:A	donor_gain	1.0000
17:1534098:C:CG	donor_gain	1.0000
17:1534098:CT:C	donor_gain	1.0000
17:1534098:CTT:C	donor_gain	1.0000
17:1534098:CTTC:C	donor_gain	1.0000
17:1534098:CTTCA:C	donor_gain	1.0000
17:1534100:T:TA	donor_gain	1.0000
17:1534218:CTTG:C	acceptor_gain	1.0000
17:1534219:TTG:T	acceptor_gain	1.0000
17:1534220:TG:T	acceptor_gain	1.0000
17:1534222:C:CC	acceptor_gain	1.0000
17:1534224:A:C	acceptor_gain	1.0000
17:1535177:CTTA:C	donor_loss	1.0000
17:1535178:TTAC:T	donor_loss	1.0000
17:1535179:TA:T	donor_loss	1.0000
17:1535180:A:AC	donor_gain	1.0000
17:1535180:AC:A	donor_gain	1.0000
17:1535180:ACC:A	donor_loss	1.0000
17:1535181:C:CA	donor_gain	1.0000
17:1535181:CC:C	donor_gain	1.0000
17:1535181:CCT:C	donor_gain	1.0000
17:1535181:CCTT:C	donor_gain	1.0000
17:1535181:CCTTA:C	donor_gain	1.0000
17:1535289:CTTG:C	acceptor_gain	1.0000
17:1535298:T:TC	acceptor_gain	1.0000

AlphaMissense

1797 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:1534136:C:G	R244P	1.000
17:1534164:A:G	W235R	1.000
17:1534164:A:T	W235R	1.000
17:1535227:G:C	F200L	1.000
17:1535227:G:T	F200L	1.000
17:1535229:A:G	F200L	1.000
17:1535245:T:A	K194N	1.000
17:1535245:T:G	K194N	1.000
17:1541595:G:C	H115D	1.000
17:1548303:G:C	C94W	1.000
17:1548318:A:C	N89K	1.000
17:1548318:A:T	N89K	1.000
17:1548323:A:G	W88R	1.000
17:1548323:A:T	W88R	1.000
17:1548330:C:A	E85D	1.000
17:1548330:C:G	E85D	1.000
17:1548370:A:T	V72D	1.000
17:1553021:C:A	K60N	1.000
17:1553021:C:G	K60N	1.000
17:1553023:T:C	K60E	1.000
17:1553086:C:G	G39R	1.000
17:1553116:C:G	A29P	1.000
17:1553133:A:G	L23P	1.000
17:1553133:A:T	L23Q	1.000
17:1553139:C:T	G21E	1.000
17:1534106:A:G	L254P	0.999
17:1534126:T:A	E247D	0.999
17:1534126:T:G	E247D	0.999
17:1534127:T:A	E247V	0.999
17:1534139:A:T	I243N	0.999

dbSNP variants (sampled 300 via entrez): RS1000015190 (17:1528241 A>G), RS1000032744 (17:1534763 T>C), RS1000101300 (17:1535769 G>A), RS1000104661 (17:1524334 G>A,T), RS1000195913 (17:1547666 T>A,C), RS1000226387 (17:1544613 G>A), RS1000267913 (17:1560113 G>A), RS1000478608 (17:1544736 G>A,C), RS1000487794 (17:1534352 G>A,T), RS1000515763 (17:1538103 A>G), RS1000604571 (17:1563484 T>A), RS1000651828 (17:1537838 T>A), RS1000677254 (17:1543825 A>T), RS1000797504 (17:1549366 G>T), RS1000815201 (17:1534046 T>C)

Disease associations

OMIM: gene MIM:600174 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST003830_2	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)	5.000000e-09
GCST009391_104	Metabolite levels	7.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0005921	FEV change measurement
EFO:0009767	glycine measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression	5
bisphenol A	decreases expression, increases expression	2
sodium arsenite	decreases expression, increases expression	2
Acetaminophen	increases expression	2
Rotenone	decreases expression, increases expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
dicrotophos	increases expression	1
testosterone enanthate	affects expression	1
triphenyl phosphate	affects expression	1
propylparaben	increases expression	1
trichostatin A	affects expression	1
methylparaben	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
azoxystrobin	decreases expression	1
CGP 52608	affects binding, increases reaction	1
deguelin	decreases expression	1
fenpyroximate	decreases expression	1
4-chloro-N-((4-(1,1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
pyrimidifen	decreases expression	1
bisphenol B	increases expression	1
pyrachlostrobin	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
picoxystrobin	decreases expression	1
bisphenol AF	increases expression	1
Norethindrone Acetate	affects cotreatment, increases expression	1
Antimycin A	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Doxorubicin	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.